| Date | Title | Description | Source |
| 14.09.2018 | Icagen Raises $7.25 Million, Bringing its Total to $20.75 Mi... | Drug development company Icagen Inc. raised $7.25 million from one investor, according to a filing w... | citybizlis... |
| 14.09.2018 | Icagen Raises $7.25 Million, Bringing its Total to $20.75 Mi... | Drug development company Icagen Inc. raised $7.25 million from one investor, according to a filing w... | archive.ci... |
| 13.04.2018 | Durham-based Icagen Raises $2 Million | Icagen Inc., a pharmaceutical development company, has raised $2 million, according to a filing with... | archive.ci... |
| 13.04.2018 | Durham-based Icagen Raises $2 Million | Icagen Inc., a pharmaceutical development company, has raised $2 million, according to a filing with... | citybizlis... |
| 30.04.2017 | Durham’s Icagen Raises $1.5 Million in Private Offering | Icagen Inc., a Durham-based drug discovery company, sold $1.5 million in shares in a private offerin... | archive.ci... |
| 30.04.2017 | Durham’s Icagen Raises $1.5 Million in Private Offering | Icagen Inc., a Durham-based drug discovery company, sold $1.5 million in shares in a private offerin... | citybizlis... |
| 13.09.2011 | PFE gives ICGN shareholders last chance to accept $56M deal | “The subsequent offering period is now scheduled to expire at 6 p.m., New York City time, on Monday,... | medcitynew... |
| 06.09.2011 | Pfizer secures enough shares for Icagen acquisition | Pfizer’s initial offer for Durham, North Carolina-based Icagen had been challenged by some Icagen sh... | medcitynew... |
| 02.09.2011 | Pfizer’s Icagen offer extended again; now expires at 6 p.m.... | Today’s extension is the second in as many days. As of midnight Thursday, the deadline of the first ... | medcitynew... |
| 01.09.2011 | Pfizer extends Icagen offer; remains just shy of shares need... | The agreement for a Pfizer acquisition of Icagen was announced on July 20, a cash deal valued at $6 ... | medcitynew... |
| 26.08.2011 | PFE to ICGN shareholders: ‘$6 per share is our best and fina... | In June, speculation that Pfizer was interested in buying drug partner Icagen sent the Durham, North... | medcitynew... |
| 22.08.2011 | At-the-market offering for biotech funding? Review 4 quick p... | That’s just over 2 percent of the $8.2 billion raised through ATM offerings in 2010. Nonetheless, co... | medcitynew... |
| 12.08.2011 | Investors blocking PFE’s $56M ICGN bid say firm’s value coul... | Two Icagen (NASDAQ:ICGN) institutional investors opposed to Pfizer‘s (NYSE:PFE) $56 million offer fo... | medcitynew... |
| 10.08.2011 | Pfizer-Icagen deal: PFE’s $56M cash offer for ICGN beat two ... | Pfizer‘s (NYSE:PFE) $56 million offer to acquire Icagen (NASDAQ:ICGN) followed a mostly fruitless co... | medcitynew... |
| 29.07.2011 | Pfizer-Icagen deal faces problem: Merlin Nexus opposes price | Pfizer’s (NYSE:PFE) $56 million bid to acquire Icagen (NASDAQ:ICGN) faces a big hurdle — two of Icag... | medcitynew... |
| 20.07.2011 | Pfizer acquires Icagen for $56 million | Pfizer and Icagen have partnered for the last four years to develop Icagen’s pain drug compounds. Ic... | medcitynew... |
| 28.06.2011 | Pfizer-Icagen merger: What ICGN could bring to PFE’s portfol... | Here are the areas targeted by Icagen’s ion channel research:
Pain and epilepsy. The ICA-105665 is ... | medcitynew... |
| 27.06.2011 | Could NC biotech Icagen get acquired by Pfizer? | Icagen stock price more than doubled to $5 per share on Friday as investors reacted positively to Pf... | medcitynew... |
| 26.04.2011 | N.C. pharma Icagen names Krafte chief scientific officer | Icagen is collaborating with Pfizer (NYSE:PFE) to develop drug candidates to treat pain. Icagen’s co... | medcitynew... |
| 29.03.2011 | North Carolina pharma R&D funding: A snapshot of 2010 | Promoted
Covid-19’s terrible toll on diabetes patients. What can be done?
The public health crisis... | medcitynew... |
| 07.03.2011 | Pfizer milestone payment for pain treatment lifts Icagen rev... | Promoted
Covid-19’s terrible toll on diabetes patients. What can be done?
The public health crisis... | medcitynew... |
| 02.02.2011 | Icagen’s epilepsy drug study gets FDA OK to resume | Promoted
Telemedicine’s potential to provide healthcare to the world’s most vulnerable
Teladoc Hea... | medcitynew... |
| - | Icagen’s epilepsy drug study gets FDA OK to resume | Drug development company Icagen is now free to move ahead with clinical trials on its epilepsy drug ... | medcitynew... |
| - | Pfizer-Icagen deal: PFE’s $56M cash offer for ICGN beat two ... | Pfizer‘s (NYSE:PFE) $56 million offer to acquire Icagen (NASDAQ:ICGN) followed a mostly fruitless co... | medcitynew... |
| - | Pfizer-Icagen deal faces problem: Merlin Nexus opposes price | Pfizer’s (NYSE:PFE) $56 million bid to acquire Icagen (NASDAQ:ICGN) faces a big hurdle — two of Icag... | medcitynew... |
| - | Pfizer-Icagen merger: What ICGN could bring to PFE’s portfol... | Pfizer (NYSE:PFE) is now talking about a possible acquisition of Icagen (NASDAQ:ICGN). But, already,... | medcitynew... |
| - | Pfizer acquires Icagen for $56 million | Pfizer (NYSE:PFE) will acquire North Carolina drug development company Icagen (NASDAQ:ICGN) for $56 ... | medcitynew... |
| - | At-the-market offering for biotech funding? Review 4 quick p... | When it needed to raise $3.7 million for ongoing clinical trials earlier this year, Icagen (NASDAQ:I... | medcitynew... |
| - | Pfizer extends Icagen offer; remains just shy of shares need... | Pfizer‘s (NYSE:PFE) $56 million offer for Icagen (NASDAQ:ICGN) has been extended one more day as the... | medcitynew... |
| - | Pfizer’s Icagen offer extended again; now expires at 6 p.m.... | Icagen‘s (NASDAQ:ICGN) sale to Pfizer (NYSE:PFE) hangs in the balance by 39,799 shares.
That’s the ... | medcitynew... |
| - | PFE to ICGN shareholders: ‘$6 per share is our best and fina... | Pfizer (NYSE:PFE) will not raise its offer to acquire Icagen (NASDAQ:ICGN).
The pharmaceutical gian... | medcitynew... |
| - | Could NC biotech Icagen get acquired by Pfizer? | Pfizer (NYSE:PFE) is taking a hard look at acquiring the NC biotech company Icagen (NASDAQ:ICGN) in ... | medcitynew... |
| - | PFE gives ICGN shareholders last chance to accept $56M deal | Nearly one-third of Icagen (NASDAQ:ICGN) shareholders have yet to accept Pfizer‘s (NYSE:PFE) $56 mil... | medcitynew... |
| - | North Carolina pharma R&D funding: A snapshot of 2010 | Research and development spending dollars reached a record $67.4 billion in 2010, a $1.5 billion inc... | medcitynew... |
| - | Investors blocking PFE’s $56M ICGN bid say firm’s value coul... | Two Icagen (NASDAQ:ICGN) institutional investors opposed to Pfizer‘s (NYSE:PFE) $56 million offer fo... | medcitynew... |
| - | N.C. pharma Icagen names Krafte chief scientific officer | North Carolina biopharmaceutical company Icagen (NASDAQ:ICGN) has promoted executive Douglas Krafte ... | medcitynew... |
| - | Pfizer secures enough shares for Icagen acquisition | Pfizer‘s (NYSE:PFE) Icagen (NASDAQ:ICGN) acquisition is a go.
After two extensions last week, Pfize... | medcitynew... |
| - | Pfizer milestone payment for pain treatment lifts Icagen rev... | A Pfizer milestone payment of $1 million in the fourth quarter helped boost Icagen’s revenue to $2.3... | medcitynew... |
